Performance of multitarget stool DNA testing in African American patients
- 7 September 2018
- Vol. 124 (19) , 3876-3880
Abstract
BACKGROUND: Multitarget stool DNA (mt‐sDNA) is an approved method for colon cancer screening that is especially relevant for patients who cannot undergo colonoscopy. Although the test performance has been evaluated in a large clinical trial, it was limited to a predominantly white population. Given differences in the epidemiology and biology of colon cancer in African American individuals, the authors sought to compare the performance of mt‐sDNA between racial groups. METHODS: The authors prospectively identified patients aged ≥40 years who were referred for colonoscopy at an academic medical center and 2 satellite facilities. Prior to the colonoscopy, the authors collected stool for mt‐sDNA and fecal immunochemical testing (FIT). They compared the sensitivity, specificity, and receiver operating characteristic curve between African American and white patients for the detection of advanced lesions or any adenoma. RESULTS: A total of 760 patients were included, 34.9% of whom were African American. The prevalence of any adenoma (38.9% for African American patients and 33.9% for white patients) and that for advanced lesions (6.8% and 6.7%, respectively) were similar between groups. The overall sensitivities of mt‐sDNA for the detection of advanced lesions and any adenoma were 43% and 19%, respectively, and the specificities were 91% and 93%, respectively. In general, mt‐sDNA was more sensitive and less specific than FIT. When stratified by race, the sensitivity, specificity, and receiver operating characteristic curve area were similar between African American and white patients for both mt‐sDNA and FIT. CONCLUSIONS: Test performance characteristics of mt‐sDNA were comparable in African American and white patients. Given the lower uptake of colonoscopy in African American individuals, mt‐sDNA may offer a promising screening alternative in this patient population.Keywords
Funding Information
- National Institutes of Health (P50CA150964)
- National Institutes of Health (P50CA150964)
- National Institutes of Health (P50CA150964)
- Case Comprehensive Cancer Center, Case Western Reserve University (P30CA43703)
- University of Michigan (P50CA130810)
- University of Michigan Comprehensive Cancer Center (P30CA046592)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097948)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097948)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097948)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK097948)
This publication has 13 references indexed in Scilit:
- Stool DNA Testing for Screening Detection of Colorectal Neoplasia in Alaska Native PeopleMayo Clinic Proceedings, 2016
- Stool DNA-based versus colonoscopy-based colorectal cancer screening: patient perceptions and preferencesFamily Medicine and Community Health, 2015
- Screening for Colorectal Cancer in African Americans: Determinants and Rationale for an Earlier Age to Commence ScreeningDigestive Diseases and Sciences, 2014
- Multitarget Stool DNA Testing for Colorectal-Cancer ScreeningNew England Journal of Medicine, 2014
- Understanding Current Racial/Ethnic Disparities in Colorectal Cancer Screening in the United StatesAmerican Journal of Preventive Medicine, 2014
- Cancer statistics for African Americans, 2013CA: A Cancer Journal for Clinicians, 2013
- Racial Disparities in Stage-Specific Colorectal Cancer Mortality: 1960–2005American Journal of Public Health, 2010
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational StudiesAnnals of Internal Medicine, 2007
- Polyp Miss Rate Determined by Tandem Colonoscopy: A Systematic ReviewAmerican Journal of Gastroenterology, 2006
- Colorectal Cancer in African AmericansAmerican Journal of Gastroenterology, 2005